Privi Speciality Chemicals growth gains support from flavour demand and capacity expansion

Investment View and Valuation

Motilal Oswal Financial Services, in its July 31, 2026 1QFY27 result update on Privi Speciality Chemicals, retained its Buy rating and Rs 4,400 target price. The broker views the company’s growth outlook positively because of healthy global flavour and fragrance demand, the China+1 opportunity and planned capacity additions across existing and new products.

The target price is based on 30 times FY28E EPS and implies 21 per cent upside from the report CMP of Rs 3,630.

1QFY27 Financial Performance

Privi Speciality Chemicals reported consolidated revenue of Rs 6,662 million in 1QFY27, up 19 per cent year on year and in line with Motilal Oswal’s estimate, supported by volume growth and realisations. EBITDA rose 15 per cent year on year to Rs 1,523 million, below the broker estimate of Rs 1,645 million.

EBITDA margin declined 70 basis points year on year to 22.9 per cent, versus the 25.0 per cent estimate, as gross margin contracted 650 basis points year on year to about 44 per cent amid input-cost volatility. Lower other operating expenses, down 530 basis points as a proportion of sales, partly offset the gross-margin pressure.

The working-capital cycle improved to 108 days from 141 days a year earlier. An export consignment valued at Rs 27.8 million caught fire at a CFS warehouse near JNPT; Privi Speciality Chemicals has filed an insurance claim and expects full recovery.

Capacity Expansion and Medium-Term Outlook

Management reiterated its medium-term aspiration to achieve Rs 50,000 million revenue and Rs 10,000 million EBITDA over the next three to four years, implying revenue growth guidance of 20 per cent CAGR with similar EBITDA margins.

Capacity expansion is progressing. Phase 1 is expected to increase capacity from 48,000 MT to 54,000 MT by September 2026, followed by another 12,000 MT under Phase 2 by September 2027. Phase 2 and Phase 3 are on track, with Phase 2 capex initiated. Management expects Rs 9,000 million of capex over the next two to three years for Phases 2 and 3.

Strategic Growth Opportunities

Maltol, Ethyl Maltol and China+1

A key strategic opportunity is maltol and ethyl maltol, where management aims to use the China+1 trend. More than 90-95 per cent of global production is concentrated in China.

Privi Speciality Chemicals seeks to become an integrated alternative supplier through a corn cob to furfural to maltol and ethyl maltol value chain, supported by technology, cost and supply-chain advantages and its waste-to-value CST-based approach.

Camphor and Raw-Material Sourcing

In camphor, which contributes around 4-5 per cent of revenue, Privi uses CST rather than the more volatile GTO raw material used by many peers. Management also indicated that diversified sourcing has limited the effect of geopolitical developments on raw-material availability, while limited crude-linked raw-material exposure reduces sensitivity to crude-price volatility.

PRIGIV and Key Growth Levers

PRIGIV generated Rs 180 million revenue at a 14-15 per cent EBITDA margin. Products made through PRIGIV will be supplied exclusively to Givaudan, and two further strategic partnerships are under discussion.

Motilal Oswal identifies the following as the principal growth levers:

• Capacity expansion
• Backward integration
• Entry into biomass-related biotech opportunities
• Scaling PRIGIV
• The proposed amalgamation with PFSPL and PBPL

Broker Estimates

The broker expects revenue, EBITDA and adjusted PAT CAGRs of 25 per cent, 28 per cent and 36 per cent, respectively, over FY26-FY28E. It largely retained FY27E and FY28E EPS estimates, while reducing FY27E EBITDA by 3 per cent to Rs 7,729 million. FY28E EBITDA remains Rs 10,564 million.